New Immunoassay Research Suite Enables Faster Drug and Biomarker Discovery

Abcam plc have announced the launch of a suite of immunoassay products based on its recombinant, monoclonal antibody pairs, as part of its commitment to deliver quality reagents to life science researchers at scale.

Matched antibody pairs are central to enzyme-linked immunoabsorbant assays (ELISAs), which are widely used to study secreted biomarkers, and are fundamental to research in areas such as immunology and cancer. Abcam optimises its antibody pairs to avert the reproducibility and scalability challenges previously faced by researchers, which can cause variability in results. Abcam’s matched antibody pairs use recombinant monoclonal antibody technology, such as the patented RabMAb® technology, to provide improved consistency over polyclonal antibodies. The pairs are screened for sensitive performance and rigorously tested in a variety of complex sample types including plasma, serum and cell lysates.

These optimised pairs are already part of Abcam’s SimpleStep ELISA® kits, and will now be available as stand-alone matched antibody pair kits. The new stand-alone high volume format provides greater flexibility to researchers and facilitates cost-effective drug discovery, by enabling scale up from small pilot studies to large-scale high-throughput assay platforms. 

Alejandra Solache, Head of Production, Development and Manufacturing at Abcam, said: “By providing researchers with highly optimised matched antibody pairs in a stand-alone format, we’re enabling scale up to higher-throughput assay platforms and faster drug discovery. Our recombinant monoclonal antibody pairs are inherently reproducible, providing reliable results the first time as well as supporting long-term use.”